Summary
33 / 100 · Bulios Score
What speaks for it
- Analysts expect revenue to grow by 19% this fiscal year.
- The price moves less than the market (beta 0.36).
What to watch
- Repaying its net debt would take 9.1 years of operating profit.
- It reports a profit, yet spends more cash than it brings in.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 22.6 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 9.0% a year over 5 years. Over the last 3 years it grew by 5.8% a year. For the next fiscal year analysts expect revenue to grow by 19%.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 45 USD
- Research and development 13 USD
- Sales and administration 46 USD
- Taxes and other -8.6 USD
- Net profit 4.9 USD
Net profit, industry median (Medical - Devices) 6.9 USD
Out of every 100 USD of revenue, 4.9 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.